Group 1: Company Strategies and Responses - The company plans to adopt a multi-dimensional strategy to address the impact of increased tariffs, including adjusting import/export prices and increasing R&D investment [2][3] - The company has increased its investment in R&D, leading to the development of new products through synthetic biology and fermentation technologies [3][4] - The company aims to expand its domestic market presence and explore international markets beyond the U.S. [3][4] Group 2: Financial Performance and Projections - The company's net profit attributable to shareholders increased by 23.59% year-on-year in 2024, indicating a trend of stabilization and recovery over the past three years [8] - Management expenses decreased by 8.27%, which will not affect marketing or R&D investments [3][4] - The company plans to issue convertible bonds to fund various projects, including the expansion of coenzyme Q10 production and other key projects [4][7] Group 3: Market Insights and Growth Opportunities - The global health consumption market is projected to reach $337.5 billion in 2025, with the VDS market expected to grow to $1,405 billion [12] - The company holds a 4.8% stake in iHerb, and transactions with iHerb are not classified as related-party transactions [12] - The company is focusing on expanding its product lines and enhancing its brand strategy to capture a larger market share in the health and wellness sector [4][12] Group 4: Challenges and Risk Management - The company is closely monitoring global trade dynamics, particularly the impact of U.S. tariffs, and has communicated its strategies to mitigate these risks [4][5] - The company has paused the production of hyaluronic acid due to intense price competition and is reallocating resources to more profitable products [10][11] - The company maintains a strong cash flow position, ensuring it can cover all loan principal and interest, thus managing financial risks effectively [6][11]